Jeevan Scientific Technology Limited has announced the successful completion of the US FDA Remote Regulatory Assessment process and the issuance of the corresponding assessment report. The company informed the BSE through a regulatory filing dated January 22, 2026, marking a significant milestone in its regulatory compliance journey.

FDA Assessment Details

The US FDA conducted a comprehensive Remote Regulatory Assessment and Remote Record Review of the company's clinical pharmacology facility. The assessment covered studies conducted over a specific period and involved detailed scrutiny of the company's operations and compliance standards.

Regulatory Compliance Update

This announcement represents the conclusion of a regulatory process that began earlier in 2025. The company had previously disclosed the commencement of this FDA assessment on November 7, 2025, keeping stakeholders informed throughout the process.

The successful completion of the FDA assessment demonstrates the company's commitment to maintaining international regulatory standards. The Remote Regulatory Assessment Report serves as official documentation of the FDA's review findings regarding the company's clinical pharmacology operations.

Corporate Communication

The disclosure was made under Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring transparency with investors and regulatory authorities. Managing Director Krishna Kishore Kuchipudi signed the official communication, emphasizing the importance of this regulatory milestone for the organization.

The company's proactive approach to regulatory compliance and transparent communication with exchanges reflects its commitment to maintaining high operational standards in the pharmaceutical sector.

Jeevan Scientific Technology has received multiple SEBI disclosure filings from four promoters regarding the acquisition of 30,00,000 convertible warrants through preferential allotment. All transactions were completed on January 2, with disclosures filed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Warrant Acquisition Details

Four promoters of the company acquired convertible warrants through preferential issue, representing a coordinated strategic move to increase their stakes through convertible instruments. Krishna Kishore Kuchipudi, Managing Director, led the acquisitions with the largest warrant holding.

Individual Shareholding Changes

The acquisitions have resulted in significant changes to each promoter's overall shareholding pattern in the company. While equity shareholdings remain unchanged, the addition of convertible warrants substantially increases their potential diluted stakes.

Share Capital Structure Impact

The preferential allotment of convertible warrants significantly affects the company's potential diluted share capital structure. The company's equity capital has increased from ₹15.83 crores to ₹19.92 crores, with substantial potential for further expansion upon warrant conversion.

Regulatory Compliance

All disclosures confirm that the acquirers belong to the promoter group of Jeevan Scientific Technology Limited. The filings were submitted to BSE Limited, where the company's shares are listed under scrip code 538837. All regulatory requirements under SEBI takeover regulations have been fulfilled through these comprehensive disclosures, ensuring transparency in the substantial acquisition of convertible instruments by the promoter group.